Clinical Research Directory

Inclusion Criteria: For all: * Written informed consent of the patient * Consent of participation in the national Network for Genomic Medicine in Lung Cancer (nNGM) * Advanced lung cancer with non-curative treatment option (NSCLC) * No targetable driver mutation detected, defined as no targetable drive mutation in ALK, EGFR, BRAF, HER2, MET, NTRK, RET, ROS1 * PD-L1 expression on tumor cells (TPS \< 50%) Cohort A: * Previously untreated NSCLC without curative treatment options * Sufficient pre-treatment tumor material available for the planned analyses or consenting and able to undergo additional pretreatment biopsy * Scheduled to undergo immune(chemo)therapy * Willing and able to undergo re-biopsy 6 weeks after start of immune(chemo)therapy Cohort B: * Any line of progression after firstline immune(chemo)therapy * Sufficient tumor material obtained after progression on most recent line of treatment available or willing and able to undergo re-biopsy prior to next line treatment Exclusion Criteria: * Any condition representing an unjustified risk for obtaining an additional biopsy sample (if needed) in the view of the investigator * Incapability of understanding the purpose and possible consequences of the trial * Substance abuse, medical, psychological or social conditions that may interfere with the subject's cooperation with the requirements of the trial or evaluation of the study results